Laboratory Corporation of America Holdings (NYSE:LH) CEO David P. King sold 44,687 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $156.86, for a total value of $7,009,602.82. Following the transaction, the chief executive officer now owns 258,753 shares in the company, valued at approximately $40,587,995.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David P. King also recently made the following trade(s):

  • On Tuesday, September 5th, David P. King sold 132,713 shares of Laboratory Corporation of America Holdings stock. The stock was sold at an average price of $157.06, for a total value of $20,843,903.78.

Laboratory Corporation of America Holdings (NYSE LH) traded down 0.28% during midday trading on Thursday, reaching $158.04. The company’s stock had a trading volume of 555,545 shares. The firm has a 50 day moving average of $156.81 and a 200 day moving average of $146.95. Laboratory Corporation of America Holdings has a 52-week low of $119.51 and a 52-week high of $164.22. The firm has a market cap of $16.09 billion, a P/E ratio of 22.13 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.36 EPS. Analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Laboratory Corporation of America Holdings (LH) CEO Sells $7,009,602.82 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/07/laboratory-corporation-of-america-holdings-lh-ceo-sells-7009602-82-in-stock.html.

A number of brokerages have issued reports on LH. ValuEngine upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Wednesday. Barclays PLC raised their target price on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. BidaskClub cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Finally, Credit Suisse Group cut Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 target price on the stock. in a report on Thursday, July 13th. They noted that the move was a valuation call. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $159.75.

Several institutional investors have recently bought and sold shares of the company. Regentatlantic Capital LLC grew its position in shares of Laboratory Corporation of America Holdings by 0.5% during the 2nd quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock worth $261,000 after buying an additional 8 shares during the period. Endurance Wealth Management Inc. grew its position in shares of Laboratory Corporation of America Holdings by 0.7% during the 1st quarter. Endurance Wealth Management Inc. now owns 1,510 shares of the medical research company’s stock worth $217,000 after buying an additional 10 shares during the period. Oppenheimer & Co. Inc. grew its position in shares of Laboratory Corporation of America Holdings by 0.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock worth $346,000 after buying an additional 15 shares during the period. New Amsterdam Partners LLC NY grew its position in shares of Laboratory Corporation of America Holdings by 0.7% during the 2nd quarter. New Amsterdam Partners LLC NY now owns 3,847 shares of the medical research company’s stock worth $593,000 after buying an additional 27 shares during the period. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Laboratory Corporation of America Holdings by 0.8% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 4,143 shares of the medical research company’s stock worth $594,000 after buying an additional 31 shares during the period. Institutional investors own 93.21% of the company’s stock.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.